A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multi-center, investigator masked, comparator controlled study. The
purpose of this study is to determine the efficacy and safety of NS2 in patients with
non-infectious acute anterior uveitis. Subjects will be randomized 1:1:1 to receive multiple
doses of NS2 0.5%, NS2 0.5% and Pred Forte® 1%, or Pred Forte® 1%.
Free aldehydes are thought to be related to inflammatory diseases such as uveitis. NS2, a
small molecule aldehyde trap, may decrease inflammation by lowering aldehyde levels.